Propanc Biopharma, Inc.PPCB
Price (close)
$0.60
Market cap
—
P/E
—
Revenue (TTM)
—
Net income
-$18.4M
Dividend yield
—
1-year total return
-98.7%
Net margin
—
Revenue growth
—
Debt / equity
0.01x
What Propanc Biopharma, Inc. does.
and “us” refer to Propanc Biopharma, Inc. and its consolidated subsidiary, unless otherwise indicated. In addition, references
to our “financial statements” are to our consolidated financial statements included elsewhere in this Annual Report on Form
prepare our consolidated financial statements in United States dollars and in accordance with generally accepted accounting principles
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$4.7M | -$2.0M | -$2.7M | -$2.7M | -$1.8M | -$58.9M |
| Free cash flow | — | — | — | — | — | — |
More on PPCB.
- Propanc Biopharma, Inc. summary
- Propanc Biopharma, Inc. financial statements
- Propanc Biopharma, Inc. key metrics
- Propanc Biopharma, Inc. health scores and style box
- Propanc Biopharma, Inc. earnings
- Propanc Biopharma, Inc. dividends
- Propanc Biopharma, Inc. valuation
- Propanc Biopharma, Inc. ownership and insiders
- Propanc Biopharma, Inc. peers
Figures from Propanc Biopharma, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.